Pathophysiological Significance of Dermatan Sulfate Proteoglycans Revealed by Human Genetic Disorders
1
Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya 468-8503, Japan
2
Center for Medical Genetics, Shinshu University Hospital, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan
*
Authors to whom correspondence should be addressed.
Academic Editor: Barbara Mulloy
Pharmaceuticals 2017, 10(2), 34; https://doi.org/10.3390/ph10020034
Received: 22 February 2017 / Revised: 22 March 2017 / Accepted: 24 March 2017 / Published: 27 March 2017
(This article belongs to the Special Issue Glycosaminoglycans and Proteoglycans)
The indispensable roles of dermatan sulfate-proteoglycans (DS-PGs) have been demonstrated in various biological events including construction of the extracellular matrix and cell signaling through interactions with collagen and transforming growth factor-β, respectively. Defects in the core proteins of DS-PGs such as decorin and biglycan cause congenital stromal dystrophy of the cornea, spondyloepimetaphyseal dysplasia, and Meester-Loeys syndrome. Furthermore, mutations in human genes encoding the glycosyltransferases, epimerases, and sulfotransferases responsible for the biosynthesis of DS chains cause connective tissue disorders including Ehlers-Danlos syndrome and spondyloepimetaphyseal dysplasia with joint laxity characterized by skin hyperextensibility, joint hypermobility, and tissue fragility, and by severe skeletal disorders such as kyphoscoliosis, short trunk, dislocation, and joint laxity. Glycobiological approaches revealed that mutations in DS-biosynthetic enzymes cause reductions in enzymatic activities and in the amount of synthesized DS and also disrupt the formation of collagen bundles. This review focused on the growing number of glycobiological studies on recently reported genetic diseases caused by defects in the biosynthesis of DS and DS-PGs.
View Full-Text
Keywords:
biglycan; carbohydrate sulfotransferase 14; decorin; chondroitin sulfate; dermatan sulfate; dermatan sulfate epimerase; dermatan 4-O-sulfotransferase; Ehlers-Danlos syndrome; glycosaminoglycan; proteoglycan; spondyloepimetaphyseal dysplasia.
▼
Show Figures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Mizumoto, S.; Kosho, T.; Yamada, S.; Sugahara, K. Pathophysiological Significance of Dermatan Sulfate Proteoglycans Revealed by Human Genetic Disorders. Pharmaceuticals 2017, 10, 34. https://doi.org/10.3390/ph10020034
AMA Style
Mizumoto S, Kosho T, Yamada S, Sugahara K. Pathophysiological Significance of Dermatan Sulfate Proteoglycans Revealed by Human Genetic Disorders. Pharmaceuticals. 2017; 10(2):34. https://doi.org/10.3390/ph10020034
Chicago/Turabian StyleMizumoto, Shuji; Kosho, Tomoki; Yamada, Shuhei; Sugahara, Kazuyuki. 2017. "Pathophysiological Significance of Dermatan Sulfate Proteoglycans Revealed by Human Genetic Disorders" Pharmaceuticals 10, no. 2: 34. https://doi.org/10.3390/ph10020034
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit